Table 2.
Prevalence of metabolic syndrome and its components according to criteria, by sex [% and (95%CI)]
| |
Overall |
Men |
Women |
P value |
|---|---|---|---|---|
| (N= 1240) | (N = 628) | (N=612) | ||
| Abnormal waist circumference ǂ |
20.9 (18.6-23.2) |
8.1 (6.0-10.2) |
34.0 (30.2-37.8) |
<0.001 |
| Abnormal waist circumference ǂǂ |
46.4 (43.6-49.2) |
34.7 (31.0-38.4) |
58.3 (54.4-62.2) |
<0.001 |
| Blood pressure ≥130/85 mmHg* |
28.3 (25.8-30.8) |
31.7 (28.1-35.3) |
24.8 (21.4-28.2) |
0.007 |
| HDL-Cholesterol <40 or <50 mg/dl* |
38.8 (36.1-41.5) |
33.8 (30.1-37.5) |
44.0 (40.1-47.9) |
<0.001 |
| Triglycerides ≥150 mg/dl* |
35.9 (33.2-38.6) |
41.8 (37.9-45.7) |
29.9 (26.3-33.5) |
<0.001 |
| Fasting glucose ≥100 mg/d* |
15.1 (13.1-17.1) |
15.1 (12.3-17.9) |
15.0 (12.2-17.8) |
0.9 |
| Prevalence of metabolic syndrome |
|
|
|
|
| NCEP-ATPIII |
17.2 (12.1-22.3) |
15.2 (7.9-22.5) |
19.2 (12.1-26.3) |
0.06 |
| IDF |
22.1 (17.2-27.0) |
20.7 (13.7-27.7) |
23.5 (16,5-30.5) |
0.2 |
| AHA/NHLBI | 24.7 (19.8-29.5) | 24.6 (17.7-31.4) | 24.8 (17.9-31.7) | 0.9 |
* Abnormal values or on pharmacological treatment.
ǂCutoffs by sex: NCEP-ATPIII ≥ 102 cm in men, ≥ 88 cm in women.
ǂǂCutoffs by sex: IDF and AHA/NHLBI definition ≥ 90 cm in men, ≥ 80 cm in women as the thresholds for South Americans.